Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
FR0012333284
Tue, 05.01.2021
ABIVAX
Abivax Publishes Review in Drug Discovery Today on Mechanism of Action and Transformative Potential of ABX464 as Therapy for Inflammatory Diseases
Scientific review summarizes the molecular events leading to potent anti-inflammatory effects of lead molecule ABX464, centered around the specific upregulation of microRNA-124 (miR-124)
Scientific dat [ … ]
Tue, 22.12.2020
ABIVAX
Abivax's Covid-19 Phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government's Clinical Trial Council
Research National Priority has priority for patient enrollment in clinical trials for an accelerated review and approval process with the French regulatory authorities
Effective Covid-19 treatments very much [ … ]
Mon, 21.12.2020
ABIVAX
Abivax to present at the 39th Annual J.P. Morgan Healthcare Conference ahead of major clinical milestones
PARIS, December 21, 2020 - 6:30 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, to [ … ]
Wed, 09.12.2020
ABIVAX
Abivax establishes clinical, regulatory and manufacturing framework for ABX464 phase 3 program and potential commercialization in 2021
Pivotal ABX464 clinical trials ongoing or planned for three indications: Ulcerative colitis, Crohn's disease and Covid-19
Four phase 1 studies are being initiated to generate complementary data to support the late [ … ]
Thu, 03.12.2020
ABIVAX
Abivax 2021 Financial Communication Calendar
PARIS, FRANCE, December 3, 2020 - 6:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today publishes its 2021 financial communication calenda [ … ]
Mon, 30.11.2020
ABIVAX
Abivax completes recruitment of ABX464 Phase 2b induction study in ulcerative colitis
Recruitment of 232 patients completed ahead of schedule with minimal impact by the Covid-19 pandemic
Top-line results expected to be available in Q2 2021
Maintenance open label extension Phase 2b study in UC progressing well with 130 patients enrolled and expan [ … ]
Mon, 16.11.2020
ABIVAX
Abivax Receives "Best Technology Award" at the European Mediscience Awards 2020
Recognizes innovative and unique mechanism of action of ABX464, with its antiviral, anti-inflammatory and tissue repair characteristics
In Phase 2b trial in ulcerative colitis, Phase 2a in rheumatoid arthritis, Phase 2b/3 in high-risk Covid-19 patients; pivotal Phase [ … ]
Mon, 02.11.2020
ABIVAX
Abivax announces webcast and teleconference following recent oversubscribed capital increase of EUR 28m at market price
PARIS, November 02, 2020 - 2:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases [ … ]
Thu, 29.10.2020
ABIVAX
Abivax announces the success of its oversubscribed capital increase of EUR 28m at market price
Subscribed by top-tier U.S. and European biotech investors (12 investors in total, 55% of funds raised from European investors, 45% from the U.S.)
Total financing since June 2020 amounting to EUR 84m, 2/3 non-dilutive (EUR 56m from Bpifrance, Kreos, Soc [ … ]
Tue, 13.10.2020
ABIVAX
Abivax secures EUR 15m non-dilutive financing from Kreos Capital
EUR 15m straight bonds, with no associated dilution, favorable financial conditions in interest rates and no expected transaction fees
Pre-negotiated EUR 5m additional straight bond tranche to be decided before 2020 year-end
Cash for operations extended until Q2 2021
PARIS, October [ … ]